Open Access

Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromes

  • Authors:
    • Nikolay Kalitin
    • Galina Dudina
    • Natalia Kostritsa
    • Anastasiya Sivirinova
    • Aida Karamysheva
  • View Affiliations

  • Published online on: January 26, 2023     https://doi.org/10.3892/ol.2023.13681
  • Article Number: 95
  • Copyright: © Kalitin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Vascular endothelial growth factors (VEGFs) are angiogenic factors playing a key role in tumor development. VEGFs are produced by different normal and tumor cells, including platelets, lymphocytes and mononuclear cells of peripheral blood. VEGF (VEGF‑A, VEGF‑C and VEGF‑D) and VEGFR (VEGFR1, VEGFR2 and VEGFR3) gene expression was studied in patients with myelodysplastic syndrome (MDS) to evaluate the possible prognostic role of the expression of these genes. Gene expression levels were determined using peripheral blood samples of 51 patients with MDS and 15 healthy volunteers by quantitative PCR. Expression of all VEGF and VEGFR genes was elevated in patients with MDS compared with healthy volunteers. No association of VEGF‑A expression with the hemoglobin content in peripheral blood was found. The analyses of gene expression in patients with MDS stratified by risk groups according to the International Prognostic Scoring System showed progressive augmentation of VEGF‑A gene expression from low to high‑risk groups and VEGFR1 and VEGFR2 expression from intermediate‑1 to high‑risk groups. The statistically significant difference in survival time of patients with high and low levels of VEGFR1 expression was revealed. VEGF‑A/VEGFR1 expression may be important for risk evaluation of patients with MDS.
View Figures
View References

Related Articles

Journal Cover

March-2023
Volume 25 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kalitin N, Dudina G, Kostritsa N, Sivirinova A and Karamysheva A: Evaluation of <em>VEGF</em> and <em>VEGFR</em> gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromes. Oncol Lett 25: 95, 2023
APA
Kalitin, N., Dudina, G., Kostritsa, N., Sivirinova, A., & Karamysheva, A. (2023). Evaluation of <em>VEGF</em> and <em>VEGFR</em> gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromes. Oncology Letters, 25, 95. https://doi.org/10.3892/ol.2023.13681
MLA
Kalitin, N., Dudina, G., Kostritsa, N., Sivirinova, A., Karamysheva, A."Evaluation of <em>VEGF</em> and <em>VEGFR</em> gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromes". Oncology Letters 25.3 (2023): 95.
Chicago
Kalitin, N., Dudina, G., Kostritsa, N., Sivirinova, A., Karamysheva, A."Evaluation of <em>VEGF</em> and <em>VEGFR</em> gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromes". Oncology Letters 25, no. 3 (2023): 95. https://doi.org/10.3892/ol.2023.13681